Which has preferable valuation and earnings, SN or CTEC?

Smith & Nephew has higher revenue and earnings than Convatec Group. Convatec Group is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew £7.08B 1.56 £382.79M £27.77 36.27 Convatec Group £2.49B 1.65 £188.35M £6.20 34.16

Which has higher earnings and valuation, SN or NIOX?

NIOX Group has lower revenue, but higher earnings than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew £7.08B 1.56 £382.79M £27.77 36.27 NIOX Group £48.70M 5.86 £995.88M £1.64 41.34

Is SN or NIOX more profitable?

NIOX Group has a net margin of 14.37% compared to Smith & Nephew's net margin of 10.08%. Smith & Nephew's return on equity of 12.25% beat NIOX Group's return on equity. Company Net Margins Return on Equity Return on Assets Smith & Nephew 10.08% 12.25% 4.51% NIOX Group 14.37% 10.14% 3.95%

Do analysts prefer TSTL or SN?

Smith & Nephew has a consensus price target of GBX 1,293.33, suggesting a potential upside of 28.37%. Given Smith & Nephew's stronger consensus rating and higher possible upside, analysts clearly believe Smith & Nephew is more favorable than Tristel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tristel 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Smith & Nephew 0 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher valuation & earnings, TSTL or SN?

Smith & Nephew has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tristel £49.54M 3.95 £6.54M £16.24 25.09 Smith & Nephew £7.08B 1.56 £382.79M £27.77 36.27

Is TSTL or SN more profitable?

Tristel has a net margin of 15.88% compared to Smith & Nephew's net margin of 10.08%. Tristel's return on equity of 23.64% beat Smith & Nephew's return on equity. Company Net Margins Return on Equity Return on Assets Tristel 15.88% 23.64% 9.89% Smith & Nephew 10.08% 12.25% 4.51%

Which has higher earnings and valuation, SN or EKF?

Smith & Nephew has higher revenue and earnings than EKF Diagnostics. Smith & Nephew is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew £7.08B 1.56 £382.79M £27.77 36.27 EKF Diagnostics £51.35M 2.23 £4.68M £0.47 56.81

Smith & Nephew (SN) Competitors

GBX 1,007.50 -23.00 (-2.23%)

As of 09/23/2026

Compare

SN vs. CTEC, AMS, NIOX, TSTL, and EKF

Should you buy Smith & Nephew stock or one of its competitors? Smith & Nephew's main competitors and comparable companies include Convatec Group (CTEC), Advanced Medical Solutions Group (AMS), NIOX Group (NIOX), Tristel (TSTL), and EKF Diagnostics (EKF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Smith & Nephew compare to Convatec Group?

Smith & Nephew (LON:SN) and Convatec Group (LON:CTEC) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Smith & Nephew currently has a consensus target price of GBX 1,293.33, indicating a potential upside of 28.37%. Convatec Group has a consensus target price of GBX 305.44, indicating a potential upside of 44.21%. Given Convatec Group's stronger consensus rating and higher probable upside, analysts plainly believe Convatec Group is more favorable than Smith & Nephew.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Convatec Group	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Smith & Nephew has higher revenue and earnings than Convatec Group. Convatec Group is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew	£7.08B	1.56	£382.79M	£27.77	36.27
Convatec Group	£2.49B	1.65	£188.35M	£6.20	34.16

In the previous week, Convatec Group had 2 more articles in the media than Smith & Nephew. MarketBeat recorded 2 mentions for Convatec Group and 0 mentions for Smith & Nephew. Convatec Group's average media sentiment score of 0.55 beat Smith & Nephew's score of 0.26 indicating that Convatec Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Smith & Nephew	Neutral
Convatec Group	Positive

Smith & Nephew has a net margin of 10.08% compared to Convatec Group's net margin of 4.99%. Smith & Nephew's return on equity of 12.25% beat Convatec Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew	10.08%	12.25%	4.51%
Convatec Group	4.99%	8.40%	5.01%

Smith & Nephew has a beta of 0.688, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Convatec Group has a beta of 0.765, suggesting that its share price is 24% less volatile than the broader market.

62.2% of Smith & Nephew shares are held by institutional investors. Comparatively, 68.4% of Convatec Group shares are held by institutional investors. 0.2% of Smith & Nephew shares are held by insiders. Comparatively, 1.0% of Convatec Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.9%. Convatec Group pays an annual dividend of GBX 7.25 per share and has a dividend yield of 3.4%. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Convatec Group pays out 116.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Summary

Convatec Group beats Smith & Nephew on 11 of the 18 factors compared between the two stocks.

How does Smith & Nephew compare to Advanced Medical Solutions Group?

Smith & Nephew (LON:SN) and Advanced Medical Solutions Group (LON:AMS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

62.2% of Smith & Nephew shares are held by institutional investors. Comparatively, 21.5% of Advanced Medical Solutions Group shares are held by institutional investors. 0.2% of Smith & Nephew shares are held by company insiders. Comparatively, 4.0% of Advanced Medical Solutions Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Smith & Nephew currently has a consensus target price of GBX 1,293.33, suggesting a potential upside of 28.37%. Advanced Medical Solutions Group has a consensus target price of GBX 278.33, suggesting a potential downside of 1.30%. Given Smith & Nephew's higher probable upside, research analysts clearly believe Smith & Nephew is more favorable than Advanced Medical Solutions Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Advanced Medical Solutions Group	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.9%. Advanced Medical Solutions Group pays an annual dividend of GBX 2.68 per share and has a dividend yield of 1.0%. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Advanced Medical Solutions Group pays out 59.3% of its earnings in the form of a dividend.

Smith & Nephew has higher revenue and earnings than Advanced Medical Solutions Group. Smith & Nephew is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew	£7.08B	1.56	£382.79M	£27.77	36.27
Advanced Medical Solutions Group	£228.94M	2.68	£11.22M	£4.52	62.39

In the previous week, Advanced Medical Solutions Group's average media sentiment score of 0.80 beat Smith & Nephew's score of 0.26 indicating that Advanced Medical Solutions Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Smith & Nephew	Neutral
Advanced Medical Solutions Group	Positive

Smith & Nephew has a net margin of 10.08% compared to Advanced Medical Solutions Group's net margin of 1.58%. Smith & Nephew's return on equity of 12.25% beat Advanced Medical Solutions Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew	10.08%	12.25%	4.51%
Advanced Medical Solutions Group	1.58%	1.44%	2.35%

Smith & Nephew has a beta of 0.688, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Advanced Medical Solutions Group has a beta of 0.704, meaning that its stock price is 30% less volatile than the broader market.

Summary

Smith & Nephew beats Advanced Medical Solutions Group on 10 of the 16 factors compared between the two stocks.

How does Smith & Nephew compare to NIOX Group?

Smith & Nephew (LON:SN) and NIOX Group (LON:NIOX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Smith & Nephew presently has a consensus price target of GBX 1,293.33, suggesting a potential upside of 28.37%. NIOX Group has a consensus price target of GBX 86, suggesting a potential upside of 26.84%. Given Smith & Nephew's higher probable upside, analysts plainly believe Smith & Nephew is more favorable than NIOX Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

NIOX Group has a net margin of 14.37% compared to Smith & Nephew's net margin of 10.08%. Smith & Nephew's return on equity of 12.25% beat NIOX Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew	10.08%	12.25%	4.51%
NIOX Group	14.37%	10.14%	3.95%

NIOX Group has lower revenue, but higher earnings than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew	£7.08B	1.56	£382.79M	£27.77	36.27
NIOX Group	£48.70M	5.86	£995.88M	£1.64	41.34

Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.9%. NIOX Group pays an annual dividend of GBX 1.25 per share and has a dividend yield of 1.8%. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group pays out 76.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

62.2% of Smith & Nephew shares are owned by institutional investors. Comparatively, 7.6% of NIOX Group shares are owned by institutional investors. 0.2% of Smith & Nephew shares are owned by company insiders. Comparatively, 5.1% of NIOX Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Smith & Nephew has a beta of 0.688, indicating that its stock price is 31% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

In the previous week, NIOX Group had 2 more articles in the media than Smith & Nephew. MarketBeat recorded 2 mentions for NIOX Group and 0 mentions for Smith & Nephew. Smith & Nephew's average media sentiment score of 0.26 beat NIOX Group's score of 0.00 indicating that Smith & Nephew is being referred to more favorably in the media.

Company	Overall Sentiment
Smith & Nephew	Neutral
NIOX Group	Neutral

Summary

Smith & Nephew and NIOX Group tied by winning 9 of the 18 factors compared between the two stocks.

How does Smith & Nephew compare to Tristel?

Tristel (LON:TSTL) and Smith & Nephew (LON:SN) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Tristel has a net margin of 15.88% compared to Smith & Nephew's net margin of 10.08%. Tristel's return on equity of 23.64% beat Smith & Nephew's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.88%	23.64%	9.89%
Smith & Nephew	10.08%	12.25%	4.51%

22.4% of Tristel shares are held by institutional investors. Comparatively, 62.2% of Smith & Nephew shares are held by institutional investors. 21.0% of Tristel shares are held by company insiders. Comparatively, 0.2% of Smith & Nephew shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.5%. Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.9%. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel is clearly the better dividend stock, given its higher yield and lower payout ratio.

Smith & Nephew has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£49.54M	3.95	£6.54M	£16.24	25.09
Smith & Nephew	£7.08B	1.56	£382.79M	£27.77	36.27

Tristel has a beta of 0.344, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Smith & Nephew has a beta of 0.688, suggesting that its share price is 31% less volatile than the broader market.

In the previous week, Smith & Nephew's average media sentiment score of 0.26 beat Tristel's score of 0.00 indicating that Smith & Nephew is being referred to more favorably in the news media.

Company	Overall Sentiment
Tristel	Neutral
Smith & Nephew	Neutral

Smith & Nephew has a consensus price target of GBX 1,293.33, suggesting a potential upside of 28.37%. Given Smith & Nephew's stronger consensus rating and higher possible upside, analysts clearly believe Smith & Nephew is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Smith & Nephew beats Tristel on 10 of the 17 factors compared between the two stocks.

How does Smith & Nephew compare to EKF Diagnostics?

Smith & Nephew (LON:SN) and EKF Diagnostics (LON:EKF) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Smith & Nephew has higher revenue and earnings than EKF Diagnostics. Smith & Nephew is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew	£7.08B	1.56	£382.79M	£27.77	36.27
EKF Diagnostics	£51.35M	2.23	£4.68M	£0.47	56.81

Smith & Nephew presently has a consensus price target of GBX 1,293.33, suggesting a potential upside of 28.37%. EKF Diagnostics has a consensus price target of GBX 35, suggesting a potential upside of 31.09%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe EKF Diagnostics is more favorable than Smith & Nephew.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, EKF Diagnostics had 1 more articles in the media than Smith & Nephew. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Smith & Nephew. Smith & Nephew's average media sentiment score of 0.26 beat EKF Diagnostics' score of 0.00 indicating that Smith & Nephew is being referred to more favorably in the media.

Company	Overall Sentiment
Smith & Nephew	Neutral
EKF Diagnostics	Neutral

62.2% of Smith & Nephew shares are owned by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are owned by institutional investors. 0.2% of Smith & Nephew shares are owned by company insiders. Comparatively, 40.2% of EKF Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Smith & Nephew has a net margin of 10.08% compared to EKF Diagnostics' net margin of 4.86%. Smith & Nephew's return on equity of 12.25% beat EKF Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew	10.08%	12.25%	4.51%
EKF Diagnostics	4.86%	3.58%	5.27%

Smith & Nephew has a beta of 0.688, suggesting that its share price is 31% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.499, suggesting that its share price is 50% less volatile than the broader market.

Summary

Smith & Nephew beats EKF Diagnostics on 9 of the 16 factors compared between the two stocks.

Get Smith & Nephew News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SN vs. The Competition

Export

Metric	Smith & Nephew	Healthcare Equipment & Supplies Industry	Healthcare Sector	LON Exchange
Market Cap	£11.04B	£5.63B	£7.32B	£2.88B
Dividend Yield	3.66%	1.79%	2.52%	6.22%
P/E Ratio	36.27	25.36	274.40	366.48
Price / Sales	1.56	71.01	639.79	90,069.92
Price / Cash	18.68	33.02	77.80	27.89
Price / Book	1.69	5.74	10.52	6.39
Net Income	£382.79M	£151.55M	£3.49B	£5.89B
7 Day Performance	-3.31%	-0.36%	-1.08%	-0.04%
1 Month Performance	-5.80%	-3.98%	-3.39%	6.15%
1 Year Performance	-25.26%	5.74%	15.08%	19.05%

Smith & Nephew Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SN Smith & Nephew	4.2872 of 5 stars	GBX 1,007.50 -2.2%	GBX 1,293.33 +28.4%	-23.6%	£11.04B	£7.08B	36.27	18,452	High Trading Volume
CTEC Convatec Group	4.7057 of 5 stars	GBX 215.21 +0.0%	GBX 305.44 +41.9%	-10.0%	£4.18B	£2.49B	34.71	10,000
AMS Advanced Medical Solutions Group	1.3194 of 5 stars	GBX 282.03 +0.0%	GBX 278.33 -1.3%	+30.6%	£613.70M	£228.94M	62.39	10	News Coverage Positive News
NIOX NIOX Group	1.9844 of 5 stars	GBX 68 +1.5%	GBX 86 +26.5%	-7.9%	£286.19M	£48.70M	41.46	92
TSTL Tristel	N/A	GBX 406.10 +0.3%	N/A	+11.9%	£195.22M	£49.54M	25.01	208

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:SN) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Smith & Nephew (SN) Competitors

SN vs. CTEC, AMS, NIOX, TSTL, and EKF

How does Smith & Nephew compare to Convatec Group?

Summary

How does Smith & Nephew compare to Advanced Medical Solutions Group?

Summary

How does Smith & Nephew compare to NIOX Group?

Summary

How does Smith & Nephew compare to Tristel?

Summary

How does Smith & Nephew compare to EKF Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SN vs. The Competition

Smith & Nephew Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Smith & Nephew (SN) Competitors

SN vs. CTEC, AMS, NIOX, TSTL, and EKF

How does Smith & Nephew compare to Convatec Group?

Do analysts recommend SN or CTEC?

Which has preferable valuation and earnings, SN or CTEC?

Does the media prefer SN or CTEC?

Is SN or CTEC more profitable?

Which has more volatility & risk, SN or CTEC?

Do institutionals & insiders hold more shares of SN or CTEC?

Is SN or CTEC a better dividend stock?

Summary

How does Smith & Nephew compare to Advanced Medical Solutions Group?

Do institutionals and insiders believe in SN or AMS?

Do analysts prefer SN or AMS?

Is SN or AMS a better dividend stock?

Which has preferable valuation and earnings, SN or AMS?

Does the media prefer SN or AMS?

Is SN or AMS more profitable?

Which has more volatility & risk, SN or AMS?

Summary

How does Smith & Nephew compare to NIOX Group?

Do analysts prefer SN or NIOX?

Is SN or NIOX more profitable?

Which has higher earnings and valuation, SN or NIOX?

Is SN or NIOX a better dividend stock?

Do insiders and institutionals hold more shares of SN or NIOX?

Which has more volatility & risk, SN or NIOX?

Does the media prefer SN or NIOX?

Summary

How does Smith & Nephew compare to Tristel?

Is TSTL or SN more profitable?

Do insiders and institutionals have more ownership in TSTL or SN?

Is TSTL or SN a better dividend stock?

Which has higher valuation & earnings, TSTL or SN?

Which has more volatility and risk, TSTL or SN?

Does the media prefer TSTL or SN?

Do analysts prefer TSTL or SN?

Summary

How does Smith & Nephew compare to EKF Diagnostics?

Which has higher earnings and valuation, SN or EKF?

Do analysts rate SN or EKF?

Does the media refer more to SN or EKF?

Do insiders and institutionals hold more shares of SN or EKF?

Is SN or EKF more profitable?

Which has more volatility & risk, SN or EKF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SN vs. The Competition

Smith & Nephew Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools